Serum IL-23, IL-17 and TNF-α level as Psoriasis severity markers: A hospital based cross sectional study.
DOI:
https://doi.org/10.3329/jssmc.v14i2.73171Keywords:
Psoriasis; Interleukin; Psoriasis Area and Severity IndexAbstract
Background: Psoriasis is an autoimmune chronic inflammatory disease where serum cytokines are marked as prime drivers of disease progression and severity. Objectives: To investigate serum TNF-α, IL-17 and IL-23 level according to disease severity of psoriasis.
Methods: A total of 35 psoriasis patients and 35 healthy controls were enrolled. Disease severity of psoriatic patients was assessed by Psoriasis Area and Severity Index (PASI) scoring. Serum TNF-α, IL-17 and IL-23 of study subjects were measured by ELISA.
Results: Serum level of is significantly increased in psoriasis patients than healthy controls. Among 35 patient 56.7% were suffering from moderate to severe psoriasis. Serum TNF-α level was more in mild group (P =0.70) and serum IL-23 level increased in moderate to severe psoriasis (P=0.42). Whereas serum IL-17 level significantly increased along with disease severity (P=0.03).
Conclusion: Our study underscores the role of TNF-α, IL-17 and IL-23 in disease severity of psoriasis.
J Shaheed Suhrawardy Med Coll 2022; 14(2): 25-29
Downloads
60
60
